AAV, CRISPR Cas9, CAR-T Cell Therapies Flashcards

1
Q

What was the first successful gene therapy trial using viral vectors treating?

A

ADA-SCID (adenosine deaminase severe combined immunodeficiency)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are some of the attractive gene delivery properties of AAV?

A

It’s non-pathogenic
Able to package and express foreign genes
Transduce dividing and non-dividing cells
Long-term gene expression in some cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the categories of genes which make up the AAV genome?

A

Replication and packaging

Viral capsid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Why does it matter that there are different AAV serotypes?

A

They differ in tropism, transduction efficiency, and how they act

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the significance of helper-free recombination?

A

It meant that adenovirus didn’t need to be used so there was no purification step required

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is Glybera?

A

It was a medication used to treat hereditary lipoprotein lipase deficiency which causes severe pancreatitis
Discontinued after 5 years on the market in 2017 because of high cost and little demand

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is Zolgensma?

A

Medication used to treat SMA by using AAV9 to deliver a functioning copy of the SMN1 gene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are some drawbacks to the use of AAV therapeutics?

A

low transduction efficiencies in certain tissues
Packaging capacity is pretty small
Vector toxicity
Presence of pre-existing neutralizing antibodies in patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What two types of RNA are required by the CRISPR Cas9 system?

A

Guide RNA both recruits Cas9 (scaffold function) and has a complementary sequence that can bind to the DNA (spacer function)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What was the first use of CRISPR-Cas9 in therapy?

A

for beta thalassemia by activating the gene for fetal hemoglobin in hematopoietic stem cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the main drawback to the CRISPR system?

A

It can create mutations elsewhere in the genome known as ‘off-target’ modifications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How was CRISPR discovered?

A

In bacteria as an adaptive immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How can off-target effects be mitigated in CRISPR?

A

Guide RNA modification and engineering

Improved Cas variants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are T-cells role in fighting cancer?

A

Some find and directly kill cancer cells; other recruit other immune cells; some suppress the immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Why do T-cells fail at fighting cancer?

A
Tumor associated antigen expression decrease 
HLA molecule down regulation
Co-stimulation molecule down regulation
TCR signaling blocked
T-cell activation failed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are characteristics of CAR?

A

It is a special receptor designed to bind antigens on cancer cells which has better specificity, is MHC independent, and has enhanced T-cell activity

17
Q

What CAR T-Cell immunotherapies are on the market?

A

Kymriah for treating acute lymphoblastic leukemia and diffuse large B-cell Non-Hodgkin Lymphoma
Yescarta has also been approved to treat non-Hodgkin B-cell lymphoma and follicular lymphoma